We are live on
!
Find out more
ORI
Oak Ridge Investments Portfolio holdings
AUM
$1.77B
1-Year Est. Return
63.16%
This Fund
S&P 500
This Quarter
Est. Return
+11.47%
1 Year Est. Return
+63.16%
3 Year Est. Return
+207.98%
5 Year Est. Return
+285.85%
10 Year Est. Return
+1,406.08%
AUM
$1.81B
AUM Growth
+$46.7M
(+2.6%)
Cap. Flow
-$117M
Cap. Flow
% of AUM
-6.44%
Top 10 Holdings %
Top 10 Hldgs %
23.31%
Holding
167
New
11
Increased
22
Reduced
127
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insulet
PODD
|
+$12.3M |
| 2 |
Evolent Health
EVH
|
+$9.38M |
| 3 |
CBM
Cambrex Corporation
CBM
|
+$9.24M |
| 4 |
Arrowhead Research
ARWR
|
+$6.23M |
| 5 |
Nomad Foods
NOMD
|
+$5.88M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVRO
NEVRO CORP.
NVRO
|
+$18.3M |
| 2 |
Sarepta Therapeutics
SRPT
|
+$10.6M |
| 3 |
MaxLinear
MXL
|
+$9.45M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
+$9.37M |
| 5 |
RSPP
RSP Permian, Inc.
RSPP
|
+$7.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.84% |
| 2 | Healthcare | 21.94% |
| 3 | Industrials | 14.87% |
| 4 | Consumer Discretionary | 13.92% |
| 5 | Consumer Staples | 6.02% |
Similar funds
CGH
KOCAA
SW
GD
HHAM
FFS
SLF
NMC
Oak Ridge Investments's Q3 2018 Portfolio in Review
As of Q3 2018, Oak Ridge Investments held 167 positions worth $1.81B, up 2.6% from $1.76B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Oak Ridge Investments withdrew a net $117M in Q3 2018, closing 6 positions and reducing 127 holdings. Its most notable exit was NEVRO CORP., an estimated $18.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 24% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Oak Ridge Investments opened a new position in Insulet worth $13.9M.
- Oak Ridge Investments's largest Q3 2018 buy was Insulet: 130,935 shares worth $13.9M.
- Oak Ridge Investments added most to Nomad Foods in Q3 2018, an estimated $5.88M increase.
- Oak Ridge Investments's biggest Q3 2018 reduction was Sarepta Therapeutics, cutting an estimated $10.6M.
- Oak Ridge Investments fully exited NEVRO CORP. in Q3 2018, selling an estimated $18.3M.
- Oak Ridge Investments's ten largest holdings make up 23% of its $1.81B portfolio in Q3 2018.
- Oak Ridge Investments opened 11 new positions and closed 6 in Q3 2018.
- Oak Ridge Investments's portfolio value rose 2.6% quarter-over-quarter to $1.81B.
Based on Oak Ridge Investments's 13F filing for Q3 2018, filed 7 Nov 2018.